T2 Biosystems to Participate at Clinical Conferences in June and July 2021
June 21 2021 - 8:00AM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid
detection of sepsis-causing pathogens, today announced the
Company’s participation in three virtual conferences this summer.
The Company will take part in the American Society for
Microbiology’s (ASM) and Federation of European Microbiological
Societies’ (FEMS) World Microbe Forum; Sepsis Alliance’s inaugural
Sepsis Tech and Innovation 2021 conference; and the European
Society of Clinical Microbiology and Infectious Diseases’ (ESCMID)
31st European Congress of Clinical Microbiology & Infectious
Diseases (ECCMID).
“Nearly 20 percent of all global deaths are due to sepsis, and
managing it is very costly for hospitals, making sepsis a top
priority for industry professionals to tackle,” said CEO John
Sperzel. “We’re looking forward to connecting with like-minded
peers in the global medical community to discuss how our rapid
diagnostic technology can be more effective than standard blood
cultures to reach our common goal of better managing bloodstream
infections and sepsis.”
At the World Microbe Forum, taking place June 20-24, T2
Biosystems’ Chief Medical Officer, Dr. Aparna Ahuja, will join Dr.
James Snyder from the University of Louisville Hospital and Dr.
Todd McCarty from the University of Alabama School of Medicine to
present the Industry and Science Symposia, “Culture Independent
Rapid Diagnostics Impact on Sepsis Management.” They will discuss
the implementation process of T2 Biosystems’ T2Candida® Panel and
T2Bacteria® Panel, and will specifically highlight the T2Candida®
Panel’s utilization impact on clinical outcomes. The presentation
will be available to view on-demand beginning on June 20th at
12:30pm ET on the World Microbe Forum portal.
On June 23 at 2:45 p.m. EDT during the inaugural Sepsis Tech
& Innovation conference, Dr. Ahuja and Dr. Debbie Goff from
Ohio State University will deliver the Industry Keynote, “Breaking
New Ground in Sepsis Diagnosis and Management with
Non-Culture-Based Tests.” They will cover the impact of sepsis on
health care costs and patient outcomes as well as the critical
importance of time to appropriate therapy in sepsis patients.
Lastly, on July 12 at 9:30 a.m. CET during ECCMID, Dr. Thomas
Walsh from Weill Cornell Medicine and Dr. Tamara Seitz from SMZ
Süd Vienna will join Dr. Ahuja, to participate in the Integrated
Symposium, “The Crucial Role of Rapid Diagnostics in the Early
Detection of Secondary Bacterial and Fungal Infections Complicating
COVID-19.”
T2 Biosystems is committed to overcoming the challenges
associated with diagnosing and treating BSIs and sepsis, namely due
to the lengthy time it currently takes to receive blood culture
results, which typically takes days. T2 Biosystems’ T2Bacteria® and
T2Candida® panels use T2MR® technology and provide results directly
from whole blood. They are the only FDA-cleared tests to identify
sepsis-causing pathogens directly from whole blood without the
wait for blood culture. This enables rapid, targeted therapy, which
can help save lives and reduce hospital costs.
About T2 BiosystemsT2 Biosystems, a leader
in the rapid detection of sepsis-causing pathogens, is dedicated to
improving patient care and reducing the cost of care by helping
clinicians effectively treat patients faster than ever before. T2
Biosystems’ products include the T2Dx® Instrument, T2Candida®
Panel, the T2Bacteria® Panel, the T2ResistanceTM Panel, and
the T2SARS-CoV-2™ Panel and are powered by the proprietary T2
Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active
pipeline of future products, including the T2CaurisTM Panel, and
T2Lyme TM Panel, as well as additional products for the detection
of bacterial and fungal pathogens and associated antimicrobial
resistance markers, and biothreat pathogens.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including, without limitation, statements regarding the ability of
T2 Biosystems products to save lives and reduce hospital costs, as
well as statements that include the words “expect,” “intend,”
“plan”, “believe”, “project”, “forecast”, “estimate,” “may,”
“should,” “anticipate,” and similar statements of a future or
forward looking nature. These forward-looking statements are based
on management's current expectations. These statements are neither
promises nor guarantees, but involve known and unknown risks,
uncertainties and other important factors that may cause actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements, including, but not
limited to, (i) any inability to (a) realize anticipated benefits
from commitments, contracts or products; (b) successfully execute
strategic priorities; (c) bring products to market; (d) expand
product usage or adoption; (e) obtain customer testimonials;
(f) accurately predict growth assumptions; (g) realize anticipated
revenues; (h) incur expected levels of operating expenses; or (i)
increase the number of high-risk patients at customer facilities;
(ii) failure of early data to predict eventual outcomes;
(iii) failure to make or obtain anticipated FDA filings or
clearances within expected time frames or at all; or (iv) the
factors discussed under Item 1A. "Risk Factors" in the Company's
Annual Report on Form 10-K for the year ended December 31, 2019,
filed with the U.S. Securities and Exchange Commission, or SEC, on
March 16, 2020, and other filings the Company makes with the SEC
from time to time. These and other important factors could cause
actual results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management's estimates as of
the date of this press release. While the Company may elect to
update such forward-looking statements at some point in the future,
unless required by law, it disclaims any obligation to do so, even
if subsequent events cause its views to change. Thus, no one should
assume that the Company’s silence over time means that actual
events are bearing out as expressed or implied in such
forward-looking statements. These forward-looking statements should
not be relied upon as representing the Company's views as of any
date subsequent to the date of this press release.
Media Contact:Amanda Michelson, Vault
Communicationsamichelson@vaultcommunications.com 609-417-7077
Investor Contact:Philip Trip Taylor, Gilmartin
Groupphilip@gilmartinIR.com 415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2024 to May 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From May 2023 to May 2024